ADT intensification may not improve prostate cancer survival. Explore real-world findings and key risk factors. Read more.
Surgical journey for participants (pts) in the MATTERHORN trial: A global, randomized, phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable ...
MedPage Today on MSN
Further doubt on heart-healthiness of calcium supplements
Recurrent cardiovascular events increased in a large cohort study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results